サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：子宮頸がん診断検査の世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
市場調査レポート
商品コード
1110366

子宮頸がん診断検査の世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Cervical Cancer Diagnostic Tests Market (Diagnostic Test: Pap Smear Test, HPV Test, Colposcopy, Biopsy & Endocervical Curettage, and Other Diagnostic Tests) - Global-Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 160 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
子宮頸がん診断検査の世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年06月16日
発行: Transparency Market Research
ページ情報: 英文 160 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の子宮頸がん診断検査市場について調査分析し、市場動向、セグメント分析、地域分析、企業プロファイルなどを提供しています。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界の子宮頸がん診断検査市場

第4章 市場概要

  • イントロダクション
    • 診断検査の定義
    • 業界の進化・発展
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界の子宮頸がん診断検査市場分析と予測（2017年～2031年）
    • 市場収益予測

第5章 主要洞察

  • 技術進歩
  • 世界の主要国における疾患の有病率と発症率
  • 主要な業界イベント（合併、買収、提携など）
  • COVID-19パンデミックの業界への影響（バリューチェーンと短期・中期・長期の影響）

第6章 世界の子宮頸がん診断検査市場分析と予測：診断検査別

  • イントロダクションと定義
  • 主要な調査結果・発展
  • 市場価値予測（2017年～2031年）：診断検査別
    • 子宮頸部細胞診検査
    • HPV検査
    • 膣鏡検査
    • 生検・子宮頸管内掻爬術
    • その他の診断検査
  • 市場の魅力分析：診断検査別

第7章 世界の子宮頸がん診断検査市場分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主要な調査結果・発展
  • 市場価値予測（2017年～2031年）：エンドユーザー別
    • 病院
    • 専門クリニック
    • その他
  • 市場の魅力分析：エンドユーザー別

第8章 世界の子宮頸がん診断検査市場分析と予測：地域別

  • 主要な調査結果
  • 市場価値予測（2017年～2031年）：地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第9章 北米の子宮頸がん診断検査市場分析と予測

  • イントロダクション
    • 主要な調査結果
  • 市場価値予測（2017年～2031年）：診断検査別
    • 子宮頸部細胞診検査
    • HPV検査
    • 膣鏡検査
    • 生検・子宮頸管内掻爬術
    • その他の診断検査
  • 市場価値予測（2017年～2031年）：エンドユーザー別
    • 病院
    • 専門クリニック
    • その他
  • 市場価値予測（2017年～2031年）：国別
    • 米国
    • カナダ
  • 市場の魅力分析
    • 診断検査別
    • エンドユーザー別
    • 国別

第10章 欧州の子宮頸がん診断検査市場分析と予測

第11章 アジア太平洋の子宮頸がん診断検査市場分析と予測

第12章 ラテンアメリカの子宮頸がん診断検査市場分析と予測

第13章 中東・アフリカの子宮頸がん診断検査市場分析と予測

第14章 競合情勢

  • 市場企業 - 競合マトリクス
  • 市場シェア分析（2021年）：企業別
  • 企業プロファイル
    • Abbott
    • BD
    • Cooper Companies, Inc.
    • DYSIS Medical, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Femasys, Inc.
    • Guided Therapeutics, Inc.
    • Hologic, Inc.
    • QIAGEN
    • Quest Diagnostics Incorporated
図表

List of Table

  • Table 01: Global Cervical Cancer Diagnostic Tests Market Value (US$ Mn) Forecast, by Product, 2022-2031
  • Table 02: Global Cervical Cancer Diagnostic Tests Market Value (US$ Mn) Forecast, by End-user, 2022-2031
  • Table 03: Global Cervical Cancer Diagnostic Tests Market Value (US$ Mn) Forecast, by Region, 2022-2031
  • Table 04: North America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Country, 2022-2031
  • Table 05: North America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Product, 2022-2031
  • Table 06: North America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by End-user, 2022-2031
  • Table 07: Europe Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022-2031
  • Table 08: Europe Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Product, 2022-2031
  • Table 09: Europe Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by End-user, 2022-2031
  • Table 10: Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022-2031
  • Table 11: Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Product, 2022-2031
  • Table 12: Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by End-user, 2022-2031
  • Table 13: Latin America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022-2031
  • Table 14: Latin America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Product, 2022-2031
  • Table 15: Latin America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by End-user, 2022-2031
  • Table 16: Middle East & Africa Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022-2031
  • Table 17: Middle East & Africa Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Product, 2022-2031
  • Table 18: Middle East & Africa Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by End-user, 2022-2031

List of Figures

  • Figure 01: Global Cervical Cancer Diagnostic Tests Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Cervical Cancer Diagnostic Tests Market Value Share Analysis, by Diagnostic Test, 2021 and 2031
  • Figure 03: Global Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pap Smear Test, 2017-2031
  • Figure 04 Global Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) and Y-o-Y Growth (%), by HPV Test, 2017-2031
  • Figure 05: Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Colposcopy, 2017-2031
  • Figure 06: Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Biopsy & Endocervical Curettage, 2017-2031
  • Figure 07: Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 08: Global Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 09: Global Cervical Cancer Diagnostic Tests Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 10: Global Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017-2031
  • Figure 11: Global Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2017-2031
  • Figure 12: Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 13: Global Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 14: Global Cervical Cancer Diagnostic Tests Market Scenario, 2022-2031
  • Figure 15: Global Cervical Cancer Diagnostic Tests Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 16: Global Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 17: North America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 18: North America Cervical Cancer Diagnostic Tests Market Value Share (%), by Country, 2021 and 2031
  • Figure 19: North America Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 20: North America Cervical Cancer Diagnostic Tests Market Value Share (%), by Product, 2021 and 2031
  • Figure 21: North America Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 22: North America Cervical Cancer Diagnostic Tests Market Value Share (%), by End-user, 2021 and 2031
  • Figure 23: North America Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 24: Europe Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 25: Europe Cervical Cancer Diagnostic Tests Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 26: Europe Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 27: Europe Cervical Cancer Diagnostic Tests Market Value Share (%), by Product, 2021 and 2031
  • Figure 28: Europe Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 29: Europe Cervical Cancer Diagnostic Tests Market Value Share (%), by End-user, 2021 and 2031
  • Figure 30: Europe Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 31: Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2031
  • Figure 32: Asia Pacific Cervical Cancer Diagnostic Tests Market Value Share (%), by Country/Sub-region, 2017 and 2031
  • Figure 33: Asia Pacific Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 34: Asia Pacific Cervical Cancer Diagnostic Tests Market Value Share (%), by Product, 2021 and 2031
  • Figure 35: Asia Pacific Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Product, 2021-2031
  • Figure 36: Asia Pacific Cervical Cancer Diagnostic Tests Market Value Share (%), by End-user, 2021 and 2031
  • Figure 37: Asia Pacific Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 38: Latin America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2031
  • Figure 39: Latin America Cervical Cancer Diagnostic Tests Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 40: Latin America Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 41: Latin America Cervical Cancer Diagnostic Tests Market Value Share (%), by Product, 2021 and 2031
  • Figure 42: Latin America Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 43: Latin America Cervical Cancer Diagnostic Tests Market Value Share (%), by End-user, 2022 and 2031
  • Figure 44: Latin America Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 45: Middle East & Africa Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2031
  • Figure 46: Middle East & Africa Cervical Cancer Diagnostic Tests Market Value Share (%), by Country/Sub-region, 2022 and 2031
  • Figure 47: Middle East & Africa Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Country/Sub-region
  • Figure 48: Middle East & Africa Cervical Cancer Diagnostic Tests Market Value Share (%), by Product, 2021 and 2031
  • Figure 49: Middle East & Africa Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 50: Middle East & Africa Cervical Cancer Diagnostic Tests Market Value Share (%), by End-user, 2021 and 2031
  • Figure 51: Middle East & Africa Cervical Cancer Diagnostic Tests Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 52: Global Cervical Cancer Diagnostic Tests Market Share Analysis by Company (2021) region, 2022-2031
目次
Product Code: TMRGL736

The report provides revenue of the global cervical cancer diagnostic tests market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cervical cancer diagnostic tests market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cervical cancer diagnostic tests market.

The report delves into the competitive landscape of the global cervical cancer diagnostic tests market. Key players operating in the global cervical cancer diagnostic tests market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global cervical cancer diagnostic tests market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cervical Cancer Diagnostic Tests Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Diagnostic Test Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cervical Cancer Diagnostic Tests Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Disease Prevalence & Incidence Rate globally with key countries
  • 5.3. Key Industry Events (mergers, acquisitions, partnerships, etc.)
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Cervical Cancer Diagnostic Tests Market Analysis and Forecast, by Diagnostic Test

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 6.3.1. Pap Smear Test
    • 6.3.2. HPV Test
    • 6.3.3. Colposcopy
    • 6.3.4. Biopsy & Endocervical Curettage
    • 6.3.5. Other diagnostic tests
  • 6.4. Market Attractiveness Analysis, by Diagnostic Test

7. Global Cervical Cancer Diagnostic Tests Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by End-user, 2017-2031
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by End-user

8. Global Cervical Cancer Diagnostic Tests Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Cervical Cancer Diagnostic Tests Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 9.2.1. Pap Smear Test
    • 9.2.2. HPV Test
    • 9.2.3. Colposcopy
    • 9.2.4. Biopsy & Endocervical Curettage
    • 9.2.5. Other diagnostic tests
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Others
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Diagnostic Test
    • 9.5.2. By End-user
    • 9.5.3. By Country

10. Europe Cervical Cancer Diagnostic Tests Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 10.2.1. Pap Smear Test
    • 10.2.2. HPV Test
    • 10.2.3. Colposcopy
    • 10.2.4. Biopsy & Endocervical Curettage
    • 10.2.5. Other diagnostic tests
  • 10.3. Market Value Forecast, by End-user, 2017-2031
    • 10.3.1. Hospitals
    • 10.3.2. Specialty Clinics
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Diagnostic Test
    • 10.5.2. By End-user
    • 10.5.3. By Country Country/Sub-region

11. Asia Pacific Cervical Cancer Diagnostic Tests Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 11.2.1. Pap Smear Test
    • 11.2.2. HPV Test
    • 11.2.3. Colposcopy
    • 11.2.4. Biopsy & Endocervical Curettage
    • 11.2.5. Other diagnostic tests
  • 11.3. Market Value Forecast, by End-user, 2017-2031
    • 11.3.1. Hospitals
    • 11.3.2. Specialty Clinics
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Country Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Diagnostic Test
    • 11.5.2. By End-user
    • 11.5.3. By Country Country/Sub-region

12. Latin America Cervical Cancer Diagnostic Tests Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 12.2.1. Pap Smear Test
    • 12.2.2. HPV Test
    • 12.2.3. Colposcopy
    • 12.2.4. Biopsy & Endocervical Curettage
    • 12.2.5. Other diagnostic tests
  • 12.3. Market Value Forecast, by End-user, 2017-2031
    • 12.3.1. Hospitals
    • 12.3.2. Specialty Clinics
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Country Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Diagnostic Test
    • 12.5.2. By End-user
    • 12.5.3. By Country Country/Sub-region

13. Middle East & Africa Cervical Cancer Diagnostic Tests Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Diagnostic Test, 2017-2031
    • 13.2.1. Pap Smear Test
    • 13.2.2. HPV Test
    • 13.2.3. Colposcopy
    • 13.2.4. Biopsy & Endocervical Curettage
    • 13.2.5. Other diagnostic tests
  • 13.3. Market Value Forecast, by End-user, 2017-2031
    • 13.3.1. Hospitals
    • 13.3.2. Specialty Clinics
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Country Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Diagnostic Test
    • 13.5.2. By End-user
    • 13.5.3. By Country Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix
  • 14.2. Market Share Analysis, by Company, 2021
  • 14.3. Company Profiles
    • 14.3.1. Abbott
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Strategic Overview
    • 14.3.2. BD
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Strategic Overview
    • 14.3.3. Cooper Companies, Inc.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Strategic Overview
    • 14.3.4. DYSIS Medical, Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Strategic Overview
    • 14.3.5. F. Hoffmann-La Roche Ltd.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Strategic Overview
    • 14.3.6. Femasys, Inc.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Strategic Overview
    • 14.3.7. Guided Therapeutics, Inc.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Strategic Overview
    • 14.3.8. Hologic, Inc.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Strategic Overview
    • 14.3.9. QIAGEN
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Strategic Overview
    • 14.3.10. Quest Diagnostics Incorporated
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Strategic Overview